Login to Your Account



Activartis in Partnering Talks Armed with Phase II Survival

By Nuala Moran
Staff Writer

Tuesday, April 9, 2013

Cancer specialist Activartis Biotech GmbH will present positive survival data from the Phase II trial of its dendritic cell therapy in treating glioblastoma at the American Association of Cancer Research Wednesday, as it steps up efforts to find a partner to back a Phase III study.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription